Erasca (ERAS) financial statements

Healthcare · Biotechnology · Market cap $5.3B

Net income was -$125M.

Free cash flow was -$96M.

The diluted share count rose 1248% over the period (dilution).

Income statement

Fiscal years, from Erasca's 10-K filings with the SEC.

Fiscal year202020212022202320242025
Research and development$30M$74M$112M$104M$115M$93M
Selling, general and admin$8M$23M$33M$38M$42M$39M
Operating income-$109M-$125M-$247M-$142M-$180M-$141M
Pre-tax income————-$162M-$125M
Income tax————$0$0
Net income-$102M-$123M-$243M-$125M-$162M-$125M
EPS (diluted)-$4.83-$1.85-$1.99-$0.83-$0.69-$0.44
Diluted shares21M66M122M150M234M284M

Balance sheet

Fiscal years, from Erasca's 10-K filings with the SEC.

Fiscal year202020212022202320242025
Cash and short-term investments$119M$414M$436M$312M$298M$342M
Total current assets$120M$420M$444M$321M$309M$286M
Property, plant and equipment$2M$16M$25M$22M$16M$13M
Total assets$125M$501M$515M$395M$503M$396M
Total current liabilities$14M$26M$49M$26M$31M$29M
Total liabilities$17M$45M$103M$79M$79M$71M
Shareholders' equity-$114M$457M$412M$317M$423M$325M
Net debt-$65M-$360M-$284M-$93M-$68M-$74M

Cash flow

Fiscal years, from Erasca's 10-K filings with the SEC.

Fiscal year202020212022202320242025
Operating cash flow-$33M-$80M-$103M-$101M-$109M-$95M
Capital spending$947,000$11M$15M$2M$60,000$128,000
Free cash flow-$34M-$91M-$118M-$103M-$109M-$96M
Stock-based compensation$797,000$8M$20M$26M$27M$25M
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ERAS.
Open ERAS in Investingly

Questions

How much free cash flow does Erasca generate?

-$96M in fiscal 2025 (operating cash flow minus capital spending).

From Erasca's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.